Bonner G G, Davis P, Stropova D, Edsall S, Yamamura H I, Porreca F, Hruby V J
Departments of Biochemistry, Chemistry, and Pharmacology, University of Arizona, Tucson, Arizona 85721, USA.
J Med Chem. 2000 Feb 24;43(4):569-80. doi: 10.1021/jm9900218.
Topographically constrained analogues of the highly mu-opioid-receptor-selective antagonist CTAP (H-D-Phe-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH(2), 1) were prepared by solid-phase peptide synthesis. Replacement of the D-Phe residue with conformationally biased beta-methyl derivatives of phenylalanine or tryptophan (2R,3R; 2R,3S; 2S,3R; 2S,3S) yielded peptides that displayed widely varying types of biological activities. In an effort to correlate the observed biological activities of these analogues with their structures, two-dimensional (1)H NMR and molecular modeling was performed. Unlike the parent (1), which is essentially a pure mu antagonist with weak delta agonist activities in the MVD bioassay, the diastereomeric beta-MePhe(1)-containing peptides exhibited simultaneous delta agonism and mu antagonism by the (2R,3R)-containing isomer 2; mu antagonism by the (2R,3S)-containing isomer 3; weak mu agonism by the (2S,3R)-containing isomer 4; and delta agonism by the (2S,3S)-containing isomer 5. Incorporation of beta-MeTrp isomers into position 1 led to peptides that were mu antagonists (2R,3R), 8; (2R,3S), 9, or essentially inactive (<10%) in the MVD and GPI assays (2S,3R), 10; (2S,3S), 11. Interestingly, in vivo antinociceptive activity was predicted by neither MVD nor GPI bioactivity. When D-Trp was incorporated in position 1, the result (7) is a partial, yet relatively potent mu agonist which also displayed weak delta agonist activity. Molecular modeling based on 2D NMR revealed that low energy conformers of peptides with similar biological activities had similar aromatic pharmacophore orientations and interaromatic distances. Peptides that exhibit mu antagonism have interaromatic distances of 7.0-7.9 A and have their amino terminal aromatic moiety pointing in a direction opposite to the direction that the amino terminus points. Peptides with delta opioid activity displayed an interaromatic distance of <7 A and had their amino terminal aromatic moiety pointing in the same direction as the amino terminus.
通过固相肽合成制备了高度μ-阿片受体选择性拮抗剂CTAP(H-D-Phe-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH₂,1)的拓扑结构受限类似物。用苯丙氨酸或色氨酸的构象偏向β-甲基衍生物(2R,3R;2R,3S;2S,3R;2S,3S)取代D-Phe残基,得到了具有广泛不同类型生物活性的肽。为了将这些类似物观察到的生物活性与其结构相关联,进行了二维¹H NMR和分子建模。与母体(1)不同,母体在MVD生物测定中本质上是一种纯μ拮抗剂,具有较弱的δ激动剂活性,含非对映体β-MePhe(1)的肽通过含(2R,3R)的异构体2表现出同时的δ激动作用和μ拮抗作用;含(2R,3S)的异构体3表现出μ拮抗作用;含(2S,3R)的异构体4表现出弱μ激动作用;含(2S,3S)的异构体5表现出δ激动作用。将β-MeTrp异构体引入第1位得到的肽在MVD和GPI测定中是μ拮抗剂((2R,3R),8;(2R,3S),9),或者基本无活性(<10%)((2S,3R),10;(2S,3S),11)。有趣的是,体内抗伤害感受活性既不能通过MVD也不能通过GPI生物活性预测。当D-Trp引入第1位时,结果(7)是一种部分但相对有效的μ激动剂,其也表现出弱的δ激动剂活性。基于二维NMR的分子建模表明,具有相似生物活性的肽的低能构象具有相似的芳香药效团取向和芳香间距离。表现出μ拮抗作用的肽的芳香间距离为7.0 - 7.9 Å,并且其氨基末端芳香部分指向与氨基末端所指方向相反的方向。具有δ阿片样活性的肽的芳香间距离<7 Å,并且其氨基末端芳香部分指向与氨基末端相同的方向。